Overexpression of cyclin E isoforms correlates with poor prognosis in rectal cancer

Zhou, Yingke; Xie, Yuntao; Gu, Jin; Li, Yan; Guan, Guoxian; Liu, X.

doi:10.1016/j.ejso.2011.08.139

Cited by 18 publications

(12 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Corin et al revealed a significant correlation between high total cyclin E expression and cancer-specific survival in patients with colon cancer (17). Zhou et al found that cyclin E overexpression is a strong negative predictor for survival in patients with rectal cancer (27). The results of the study by Kitahara et al support the possibility that cyclin E gene amplification may play a role in the pathogenesis of CRC (26).…”

Section: A B Csupporting

confidence: 76%

Expression of cyclin E in stage III colorectal carcinoma

et al. 2012

View full text Add to dashboard Cite

Abstract. Carcinogenesis is characterized by an abnormal regulation of the cell cycle. Regulators of the cell cycle such as cyclin E play an important role in neoplasia and may be correlated with prognosis. The clinical significance of the expression of cyclin E in stage III colorectal carcinoma has not yet been investigated. The expression of cyclin E was evaluated in 49 patients. Using a multivariate analysis, the expression of cyclin E in the tumor at diagnosis was compared with various clinicopathological variables, including age, gender, tumor site, tumor size, tumor differentiation and lymph node involvement. There were more node-positive cases in the cyclin E-negative group than in the cyclin E-positive group (P=0.003). However, there was no correlation between the degree of cyclin E expression and the clinical data. In conclusion, our data suggest that overexpression of cyclin E does not predict the clinical outcome in colorectal cancer stage III. Negative cyclin E staining may be associated with lymph node involvement.

show abstract

Section: A B Csupporting

confidence: 76%

Expression of cyclin E in stage III colorectal carcinoma

et al. 2012

View full text Add to dashboard Cite

show abstract

“…Under normal conditions, cyclin E begins to be synthesized in G1 metaphase, reaches a peak in the G1/S phase, and rapidly descends in the S phase; and cyclin E expression is strictly regulated by cells. In abnormal conditions, a variety of factors lead to cyclin E overexpression, which activates its downstream protein to allow cell over-proliferation, leading to tumor formation (21)(22)(23).…”

Section: R E T R a C T E D Discussionmentioning

confidence: 99%

Effects of cyclin E gene silencing on the proliferation of esophageal cancer cell lines, EC9706, Eca109 and KYSE30

Wang¹,

Li²,

Zang³

et al. 2013

Molecular Medicine Reports

View full text Add to dashboard Cite

In order to observe the effects of cyclin E gene silencing by small interfering RNA (siRNA) on the growth, proliferation, invasion and apoptosis of esophageal cancer cell lines, including EC9706, Eca109 and KYSE30, siRNA vectors targeting cyclin E gene were constructed and then transfected into the EC9706, Eca109 and KYSE30 human esophageal cancer cell lines. Cyclin E mRNA and protein expression were determined by RT-PCR and western blotting. Cell proliferation and clonality were detected using a CCK-8 test and soft agar colony formation assay. Cell cycle distribution, apoptosis and invasion of EC9706, Eca109 and KYSE30 cells were evaluated with flow cytometry and a transwell culture system. After siRNA vectors targeting the cyclin E gene were transfected into EC9706, Eca109 and KYSE30 cell lines, compared with blank and negative control groups, the expression of cyclin E mRNA and protein (P<0.01), colony-forming units and the number of cells penetrating the transwell membrane (P<0.05) were significantly decreased, the cells in the S and G2/M phase were reduced, the cells in the G0/G1 phase were increased and the apoptosis rate was increased (P<0.01) in the experimental groups. Cyclin E gene silencing effectively inhibits growth, proliferation and invasion of esophageal cancer cells.

show abstract

“…Overexpression of low molecular weight cyclin E (LMW-E), which was originally discovered in breast cancer by our group and subsequently reported by others 1-7 , is also found in ovarian cancer 8,9 , melanoma 10 , colorectal cancer 11-14 , lung cancer 15 , and renal cell carcinoma 16 . LMW-E is generated from N-terminal neutrophil elastase cleavage of the 50-KDa, full-length cyclin E1 17 .…”

Section: Introductionmentioning

confidence: 90%

Cytoplasmic Cyclin E Predicts Recurrence in Patients with Breast Cancer

Hunt

Karakaş

et al. 2017

Clinical Cancer Research

View full text Add to dashboard Cite

Background Low-molecular-weight-cyclin E (LMW-E) detected by Western blot, predicts for reduced breast cancer survival, however, it is impractical for clinical use. LMW-E lacks a nuclear localization signal which leads to accumulation in the cytoplasm that can be detected by immunohistochemistry. We tested the hypothesis that cytoplasmic staining of cyclin E can be used as a predictor of poor outcome in different subtypes of breast cancer using patient cohorts with distinct clinical and pathologic features. Methods We evaluated the subcellular localization of cyclin E in breast cancer specimens from 2,494 patients from 4 different cohorts: 303 from a prospective study and 2,191 from retrospective cohorts (National Cancer Institute [NCI], MD Anderson Cancer Center [MDA] and the United Kingdom [UK]). Median follow-up times were 8.0, 10.1, 13.5, and 5.7 years, respectively. Results Subcellular localization of cyclin E on immunohistochemistry was associated with full-length (nuclear) and low molecular weight isoforms (cytoplasmic) of cyclin E on Western blot analysis. In multivariable analysis, cytoplasmic cyclin E staining was associated with the greatest risk of recurrence compared with other prognostic factors across all subtypes in three (NCI, MDA and UK) of the cohorts. In the MDA cohort, cytoplasmic cyclin E staining outperformed Ki67 and all other variables as prognostic factors. Conclusion Cytoplasmic cyclin E, identifies patients with the highest likelihood of recurrence consistently across different patient cohorts and subtypes. These patients may benefit from alternative therapies targeting the oncogenic isoforms of cyclin E.

show abstract

Overexpression of cyclin E isoforms correlates with poor prognosis in rectal cancer

Cited by 18 publications

References 23 publications

Expression of cyclin E in stage III colorectal carcinoma

Expression of cyclin E in stage III colorectal carcinoma

Effects of cyclin E gene silencing on the proliferation of esophageal cancer cell lines, EC9706, Eca109 and KYSE30

Cytoplasmic Cyclin E Predicts Recurrence in Patients with Breast Cancer

Contact Info

Product

Resources

About